Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $750.00, giving the company a market capitalization of 79.23B. It carries a P/E multiple of 18.04 and pays a dividend yield of 46.7%.
On 2026-01-24, Regeneron(REGN) stock moved within a range of $747.30 to $762.00. With shares now at $750.00, the stock is trading +0.4% above its intraday low and -1.6% below the session's peak.
Trading activity shows a volume of 676.38K, compared to an average daily volume of 926.16K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
If you are wondering whether Regeneron Pharmaceuticals at around US$755 per share still offers value, you are not alone. The answer depends on how you look at i...
Evercore ISI raised the firm’s price target on Regeneron (REGN) to $875 from $750 and keeps an Outperform rating on the shares. Regeneron is “looking strong wit...
Regeneron Pharmaceuticals (NasdaqGS:REGN) has seen the departure of Dr. Wolfgang Liedtke, its Chair of Neurology. Dr. Liedtke is joining Anavex Life Sciences i...
Analyst ratings
70%
of 30 ratingsMore REGN News
Shareholders of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) looking to boost their income beyond the stock's 0.5% annualized dividend yield can sell the June...
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Regeneron’s latest clinical update center...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on REGN stock, giving a Hold rating on January 14. Claim 50% Off TipRanks Premium Unloc...
Recently, Regeneron Pharmaceuticals’ leadership outlined a plan to prioritize internal research and development over large acquisitions as it approaches key pat...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.